KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neogenomics (NEO) Change in Accured Expenses (2016 - 2025)

Neogenomics (NEO) has disclosed Change in Accured Expenses for 16 consecutive years, with $6.9 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Change in Accured Expenses rose 269.68% year-over-year to $6.9 million, compared with a TTM value of -$4.7 million through Dec 2025, down 17.22%, and an annual FY2025 reading of -$4.7 million, down 17.22% over the prior year.
  • Change in Accured Expenses was $6.9 million for Q4 2025 at Neogenomics, up from $2.8 million in the prior quarter.
  • Across five years, Change in Accured Expenses topped out at $11.2 million in Q2 2021 and bottomed at -$15.5 million in Q2 2025.
  • Average Change in Accured Expenses over 5 years is -$184500.0, with a median of $437000.0 recorded in 2022.
  • The sharpest move saw Change in Accured Expenses plummeted 648.95% in 2021, then skyrocketed 928.26% in 2025.
  • Year by year, Change in Accured Expenses stood at -$7.6 million in 2021, then surged by 124.32% to $1.8 million in 2022, then crashed by 184.21% to -$1.6 million in 2023, then tumbled by 160.31% to -$4.1 million in 2024, then surged by 269.68% to $6.9 million in 2025.
  • Business Quant data shows Change in Accured Expenses for NEO at $6.9 million in Q4 2025, $2.8 million in Q3 2025, and -$15.5 million in Q2 2025.